למאמר המלא

Laham Y, Ringelstein-Harlev S, Kurnik D, Fineman R, Yehudai-Ofir D, Bonstein L, Setter-Marco N, Braun E, Ghersin I, Zuckerman T, Beyar-Katz O. High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies. Haematologica. 2025 Jan 9. doi: 10.3324/haematol.2024.286714. Epub ahead of print. PMID: 39781629.